Rallybio Corporation2024财年第三财季实现净利润-11.47百万美元，同比增加37.56%

市场透视11-14

11月14日，Rallybio Corporation（RLYB.US）公布财报，公告显示公司2024财年第三财季净利润为-11.47百万美元，同比增加37.56%；其中营业收入为299000.00美元，每股基本收益为-0.26美元。从资产负债表来看，Rallybio Corporation（RLYB.US）总负债8.19百万美元，其中短期债务230000.00美元，资产负债比为9.65，流动比率...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483283307?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-14 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483283307","market":"us","top_or_hot":-1,"title":"Rallybio Corporation2024财年第三财季实现净利润-11.47百万美元，同比增加37.56%","media":"市场透视","content":"<div>\n<p>11月14日，Rallybio Corporation（RLYB.US）公布财报，公告显示公司2024财年第三财季净利润为-11.47百万美元，同比增加37.56%；其中营业收入为299000.00美元，每股基本收益为-0.26美元。从资产负债表来看，Rallybio Corporation（RLYB.US）总负债8.19百万美元，其中短期债务230000.00美元，资产负债比为9.65，流动比率...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114000057a2348653&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rallybio Corporation2024财年第三财季实现净利润-11.47百万美元，同比增加37.56%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRallybio Corporation2024财年第三财季实现净利润-11.47百万美元，同比增加37.56%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114000057a2348653&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月14日，Rallybio Corporation（RLYB.US）公布财报，公告显示公司2024财年第三财季净利润为-11.47百万美元，同比增加37.56%；其中营业收入为299000.00美元，每股基本收益为-0.26美元。从资产负债表来看，Rallybio Corporation（RLYB.US）总负债8.19百万美元，其中短期债务230000.00美元，资产负债比为9.65，流动比率...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114000057a2348653&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLYB","symbol_name":"Rallybio Corp.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114000057a2348653&s=b","article_id":"2483283307","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114000057a2348653&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483283307","pubTimestamp":1731513631,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月14日，Rallybio Corporation公布财报，公告显示公司2024财年第三财季净利润为-11.47百万美元，同比增加37.56%；其中营业收入为299000.00美元，每股基本收益为-0.26美元。从资产负债表来看，Rallybio Corporation总负债8.19百万美元，其中短期债务230000.00美元，资产负债比为9.65，流动比率为9.56。机构评级：截至2024年11月14日，当前有4家机构对Rallybio Corporation目标价做出预测，其中目标均价为8.50美元，其中最低目标价为5.00美元，最高目标价为13.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"RLYB":"Rallybio Corp."},"translate_title":"Rallybio Corporation achieved net profit of-11.47 million US dollars in the third fiscal quarter of fiscal year 2024, a year-on-year increase of 37.56%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLYB":1},"content_text":"11月14日，Rallybio Corporation（RLYB.US）公布财报，公告显示公司2024财年第三财季净利润为-11.47百万美元，同比增加37.56%；其中营业收入为299000.00美元，每股基本收益为-0.26美元。从资产负债表来看，Rallybio Corporation（RLYB.US）总负债8.19百万美元，其中短期债务230000.00美元，资产负债比为9.65，流动比率为9.56。机构评级：截至2024年11月14日，当前有4家机构对Rallybio Corporation目标价做出预测，其中目标均价为8.50美元，其中最低目标价为5.00美元，最高目标价为13.00美元。公司简介：Rallybio Corp 是一家临床阶段的生物技术公司，致力于为患有严重和罕见疾病的患者寻找并加速生命转化疗法的开发。 其项目旨在预防胎儿和新生儿同种免疫性血小板减少症，这是一种可能危及生命的罕见疾病，可能导致胎儿和新生儿不受控制的出血。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483283307"}